Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used forlymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine/prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-celllymphoma. However, suboptimal response and /or resistance to rituximab have remained achallenge in the therapy of B-cell non-Hodgkin's lymphoma (NHL). Novel agents are underactive clinical trials. This review will summarize the latest development in new mAbs againstCD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106),ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab),PRO131921 and GA101 (obinutumumab).
via Journal of Hematology & Oncology
via Journal of Hematology & Oncology
No comments:
Post a Comment